S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
15 A.I. Trading Opportunities a Day (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
15 A.I. Trading Opportunities a Day (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
15 A.I. Trading Opportunities a Day (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
S&P 500   4,282.37
DOW   33,762.76
QQQ   354.65
Opera Stock: The Fast-Rising Star of AI-Driven Web Experiences
"Unknown laser company making HUGE profit from Russia-Ukraine War" (Ad)
What Should Investors Make of These 3 Dividend Cuts?
Symbotic AI Robots Disrupt Warehouse Industry, Stock Price Soars
15 A.I. Trading Opportunities a Day (Ad)
CrowdStrike: Another Tech Stock to Buy on the Dip 
Broadcom Stock Pulls into the Buy Zone: Analysts Raise Targets
“One-Stock Millionaire” IGNORES 99.9% of the Market (Ad)
Salesforce: Time to Snap it Up as the Market Buys the Dip?
Zscaler: Analysts Raise the Bar for the AI Cloud Security Company
NASDAQ:MDGL

Madrigal Pharmaceuticals (MDGL) Stock Forecast, Price & News

$259.94
-9.10 (-3.38%)
(As of 06/2/2023 ET)
Compare
Today's Range
$255.41
$271.65
50-Day Range
$234.08
$312.00
52-Week Range
$57.21
$322.67
Volume
477,100 shs
Average Volume
386,559 shs
Market Capitalization
$4.75 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$312.36

Madrigal Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.80 Rating Score
Upside/​Downside
20.2% Upside
$312.36 Price Target
Short Interest
Healthy
9.01% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.92
Upright™ Environmental Score
News Sentiment
0.39mentions of Madrigal Pharmaceuticals in the last 14 days
Based on 4 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($18.65) to ($8.31) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.29 out of 5 stars

Medical Sector

267th out of 983 stocks

Pharmaceutical Preparations Industry

120th out of 486 stocks


MDGL stock logo

About Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock

Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.

Receive MDGL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Madrigal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MDGL Stock News Headlines

We Called (ARWR) In Advance, Which Stocks Are Next?
Nearly 56% gains in 30 days! This bullish trend reversal was not only forecasted by A.I., but we called it 1 – 3 days in advance. If you have any money invested in the markets…even just your retirement, you’ll want to see this. Plus, it’s FREE - the training is only an hour & LIVE.
Madrigal Pharmaceuticals (NASDAQ:MDGL) Trading 4.1% Higher
Sell Every Stock, Except ONE (Ticker Revealed)
We saw one of the longest bull markets in history, with the S&P surging well over 800% But now the chickens have come home to roost. However, Jeff Clark couldn’t care less because he ignores almost every single stock in the market.
Why These 3 Nasdaq Stocks Buckled Today
Top Small-Cap Stocks for May 2023
Madrigal Pharmaceuticals (NASDAQ:MDGL) Trading Down 11.4%
See More Headlines

MDGL Price History

MDGL Company Calendar

Last Earnings
5/09/2023
Today
6/02/2023
Next Earnings (Estimated)
8/03/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:MDGL
CUSIP
87162T20
Employees
71
Year Founded
2011

Price Target and Rating

Average Stock Price Forecast
$312.36
High Stock Price Forecast
$390.00
Low Stock Price Forecast
$194.00
Forecasted Upside/Downside
+20.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
10 Analysts

Profitability

Net Income
$-295,350,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$8.21 per share

Miscellaneous

Free Float
12,855,000
Market Cap
$4.75 billion
Optionable
Optionable
Beta
-0.70

Social Links


Key Executives

  • Paul A. Friedman
    Chairman, President & Chief Executive Officer
  • Alex G. Howarth
    Chief Financial Officer
  • Edward Chiang
    SVP-Clinical & Technical Operations
  • Rebecca A. Taub
    Director & Chief Medical Officer
  • Stephen Dodge
    Senior Vice President-Global Medical Affairs













MDGL Stock - Frequently Asked Questions

Should I buy or sell Madrigal Pharmaceuticals stock right now?

10 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Madrigal Pharmaceuticals in the last year. There are currently 2 hold ratings and 8 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MDGL shares.
View MDGL analyst ratings
or view top-rated stocks.

What is Madrigal Pharmaceuticals' stock price forecast for 2023?

10 brokers have issued 12-month price objectives for Madrigal Pharmaceuticals' shares. Their MDGL share price forecasts range from $194.00 to $390.00. On average, they expect the company's stock price to reach $312.36 in the next twelve months. This suggests a possible upside of 20.2% from the stock's current price.
View analysts price targets for MDGL
or view top-rated stocks among Wall Street analysts.

How have MDGL shares performed in 2023?

Madrigal Pharmaceuticals' stock was trading at $290.25 at the beginning of the year. Since then, MDGL stock has decreased by 10.4% and is now trading at $259.94.
View the best growth stocks for 2023 here
.

When is Madrigal Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023.
View our MDGL earnings forecast
.

How were Madrigal Pharmaceuticals' earnings last quarter?

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced its earnings results on Tuesday, May, 9th. The biopharmaceutical company reported ($4.23) earnings per share for the quarter, beating the consensus estimate of ($4.78) by $0.55.

What other stocks do shareholders of Madrigal Pharmaceuticals own?
What is Madrigal Pharmaceuticals' stock symbol?

Madrigal Pharmaceuticals trades on the NASDAQ under the ticker symbol "MDGL."

Who are Madrigal Pharmaceuticals' major shareholders?

Madrigal Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Avoro Capital Advisors LLC (9.11%), BlackRock Inc. (5.21%), Perceptive Advisors LLC (3.56%), State Street Corp (2.84%), Assenagon Asset Management S.A. (2.85%) and FMR LLC (1.44%). Insiders that own company stock include Bay City Capital Llc, Brian Joseph Lynch, Fred B Craves, Remy Sukhija and Richard S Levy.
View institutional ownership trends
.

How do I buy shares of Madrigal Pharmaceuticals?

Shares of MDGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Madrigal Pharmaceuticals' stock price today?

One share of MDGL stock can currently be purchased for approximately $259.94.

How much money does Madrigal Pharmaceuticals make?

Madrigal Pharmaceuticals (NASDAQ:MDGL) has a market capitalization of $4.75 billion. The biopharmaceutical company earns $-295,350,000.00 in net income (profit) each year or ($18.10) on an earnings per share basis.

How can I contact Madrigal Pharmaceuticals?

Madrigal Pharmaceuticals' mailing address is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. The official website for the company is www.madrigalpharma.com. The biopharmaceutical company can be reached via phone at (267) 824-2827, via email at ir@madrigalpharma.com, or via fax at 781-274-8228.

This page (NASDAQ:MDGL) was last updated on 6/3/2023 by MarketBeat.com Staff

My Account -